News | August 10, 2024
IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Strong topline growth driven by solid performance across key brands.
Fredun Pharmaceuticals has reported total income of Rs. 78.81 crores during the period ended June 30, 2024
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Decision on EU marketing authorisation for this population expected by September 2024
Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe
Subscribe To Our Newsletter & Stay Updated
